Company profile for Circle Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Circle is developing a new paradigm for macrocycle drug discovery based on rational design and synthetic chemistry. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration. Circle’s macrocycle development platform is applicable across a wide range of serious diseases...
Circle is developing a new paradigm for macrocycle drug discovery based on rational design and synthetic chemistry. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration. Circle’s macrocycle development platform is applicable across a wide range of serious diseases; the company is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
280 Utah Avenue, Suite 100, South San Francisco, CA 94080-6883
Telephone
Telephone
650-392-0363
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260104290820/en/Circle-Pharma-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

BUSINESSWIRE
05 Jan 2026

https://www.businesswire.com/news/home/20251217473902/en/Circle-Pharma-Announces-Nomination-of-CID-165-an-Oral-First-in-class-Cyclin-D1-RxL-Inhibitor-as-Development-Candidate-for-its-Second-Oncology-Program

BUSINESSWIRE
17 Dec 2025

https://www.businesswire.com/news/home/20251130843373/en/Circle-Pharma-Appoints-Anne-E.-Borgman-M.D.-as-Chief-Medical-Officer

BUSINESSWIRE
01 Dec 2025

https://www.businesswire.com/news/home/20251103229143/en/Circle-Pharma-Announces-Participation-in-Upcoming-Investor-Conferences

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251031045482/en/Circle-Pharma-Appoints-Rob-Lauzen-as-Chief-Financial-Officer

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20251022605631/en/Circle-Pharma-Unveils-First-Preclinical-Data-from-Cyclin-D1-Program-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics

BUSINESSWIRE
23 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty